Business Context and Reporting Period
Company: Qualigen Therapeutics, Inc. (Note: Input metadata referenced "Aixcrypto," but the filing text identifies the registrant as Qualigen Therapeutics, Inc., ticker QLGN).
Reporting Period: Quarterly period ended June 30, 2025 (Form 10-Q).
Business Overview: An early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Key programs include QN-302 (pancreatic cancer) and Pan-RAS (preclinical). The company also holds a co-development agreement with Marizyme, Inc. regarding the DuraGraft vascular conduit solution.
Status: The company is a smaller reporting company with substantial doubt regarding its ability to continue as a going concern for the next 12 months due to recurring losses and negative cash flows.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Expenses | $4,408,446 | $3,166,091 |
| Net Loss | $(4,331,588) | $(3,609,309) |
| Cash and Cash Equivalents (End of Period) | $331,601 | $118,685 |
| Net Cash Used in Operating Activities | $(2,687,507) | $(2,258,118) |
| Total Current Liabilities | $5,614,956 | $2,007,483 |
| Accumulated Deficit | $(127,393,162) | $(120,411,693) |
Debt and Liquidity: As of June 30, 2025, the company held $3.47 million in promissory notes and $142,069 in convertible debt. Current liabilities significantly exceed current assets ($5.6M vs $4.0M).
Material Changes vs. Prior Period
- Expense Increase: Total expenses increased by approximately $1.24 million (39%) compared to the prior six-month period. This was driven by a $1.84 million increase in General and Administrative (G&A) expenses, largely due to $1.5 million in investor relations fees to raise capital.
- R&D Decrease: Research and Development expenses dropped significantly by $1.07 million (95%) to $50,982, as the company slowed development of therapeutic products due to financial constraints.
- Credit Loss Provision: A new credit loss expense of $468,000 was recorded for short-term notes receivable from Marizyme, Inc., reflecting an estimated allowance for expected credit losses. No such expense existed in the prior period.
- Other Income/Expense: The company recorded a net gain in "Other Expense (Income)" of $76,894, compared to a net expense of $346,216 in the prior period. This improvement was due to gains on the change in fair value of warrant liabilities ($55,199) and convertible debt ($37,874), and increased interest income ($255,430) from Marizyme notes.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. The company expects to continue incurring net losses and negative cash flows.
- Capital Raising: To address liquidity, the company borrowed $3.64 million in short-term notes from January to July 2025. Additionally, in July 2025 (subsequent event), the company closed a private placement raising approximately $4.26 million in equity.
- Unusual Items:
- Marizyme Notes: The company advanced $1.52 million to Marizyme during the period. While these notes bear 18% interest, a significant portion ($828,000) is reserved as an allowance for credit losses due to uncertainty regarding Marizyme's financial condition.
- Debt Penalties: Certain promissory notes include default penalties. The company accrued $200,000 in penalties for one note due to timing risks, amortizing this cost over the note's duration.
- Risks:
- Litigation: The company is a defendant in a lawsuit filed by LifeSci Capital LLC alleging failure to pay $503,483 in placement agent fees. The company disputes the claim.
- Internal Controls: Management identified material weaknesses in internal controls, including insufficient accounting personnel and lack of IT general controls.
- Development Delays: Clinical development for QN-302 and Pan-RAS has been slowed due to lack of funding.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.26 million raised in July 2025 to cover the $5.6 million in current liabilities and ongoing operational burn rate.
- Marizyme Exposure: Assess the recoverability of the $3.3 million net short-term note receivable from Marizyme, given the $828,000 credit loss reserve and the debtor's financial uncertainty.
- Debt Covenants and Penalties: Review the terms of the $3.47 million in promissory notes, specifically the 30% default penalties and maturity dates, to evaluate refinancing risk.
- Litigation Outcome: Monitor the status of the LifeSci Capital LLC lawsuit regarding the $503,483 alleged debt.
- Capital Structure Dilution: Evaluate the impact of recent and potential future equity issuances (Series A-2 and A-3 Preferred Stock) on common shareholder dilution.